Genetic Landscape and Biomarkers of Hepatocellular Carcinoma

Gastroenterology

Volumn 149, Issue 5, 2015, Pages 1226-1239.e4

  Zucman Rossi, Jessica ^a,b,c   Villanueva, Augusto ^d   Nault, Jean Charles ^a,b,e   Llovet, Josep M ^d,f,g  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITÉ PARIS 13   (France)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e HÔPITAL JEAN VERDIER   (France)

^f INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^g INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Genomics; Liver Cancer; Molecular Therapies; Signaling Pathways

Indexed keywords

AFLIBERCEPT; APC PROTEIN; ARISTOLOCHIC ACID; ATM PROTEIN; BETA CATENIN; BEVACIZUMAB; CABOZANTINIB; CYCLIN DEPENDENT KINASE INHIBITOR 2A; ERLOTINIB; EVEROLIMUS; FIBROBLAST GROWTH FACTOR 19; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; HEAT SHOCK PROTEIN 90 INHIBITOR; KELCH LIKE ECH ASSOCIATED PROTEIN 1; NIVOLUMAB; PALBOCICLIB; PROTEIN P53; RAPAMYCIN; REFAMETINIB; SORAFENIB; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TEMSIROLIMUS; TERTOMOTIDE; TIVANTINIB; TUMOR MARKER; VASCULOTROPIN A; VIRUS DNA; WNT PROTEIN; BIOLOGICAL MARKER; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; TERT PROTEIN, HUMAN; VEGFA PROTEIN, HUMAN;

ARTICLE; CANCER PROGNOSIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOME 9; COPY NUMBER VARIATION; DIAGNOSTIC TEST ACCURACY STUDY; ENVIRONMENTAL FACTOR; GENE MUTATION; GENETIC PREDISPOSITION; HEPATITIS B VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALIGNANT TRANSFORMATION; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TELOMERE HOMEOSTASIS; GENE AMPLIFICATION; GENETICS; GENOMICS; HEPATITIS B; METABOLISM; MUTATION; PROCEDURES; PROGNOSIS; PROMOTER REGION;

BIOMARKERS; CARCINOMA, HEPATOCELLULAR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA COPY NUMBER VARIATIONS; FIBROBLAST GROWTH FACTORS; GENE AMPLIFICATION; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HEPATITIS B; HUMANS; MUTATION; PROGNOSIS; PROMOTER REGIONS, GENETIC; TELOMERASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84943232150     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.05.061     Document Type: Article

References (166)

1. A.D. Tommaso Risk of HCC: genetic heterogeneity and complex genetics J Hepatol 52 2010 252 257
2. M. Li, D.A. Gerber, M. Koruda, and et al. Hepatocelluar carcinoma associated with attenuated familial adenomatous polyposis: a case report and review of the literature Clin Colorectal Cancer 11 2012 77 81
3. J.S.B. Willson, T.D. Godwin, G.A.R. Wiggins, and et al. Primary hepatocellular neoplasms in a MODY3 family with a novel HNF1A germline mutation J Hepatol 59 2013 904 907
4. Y. Bacq, E. Jacquemin, C. Balabaud, and et al. Familia liver adenomatosis associated with hepatocyte nuclear factor 1α inactivation Gastroenterology 125 2003 1470 1475
5. J. Calderaro, P. Labrune, G. Morcrette, and et al. Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I J Hepatol 58 2013 350 357
6. P. Nahon, and J. Zucman-Rossi Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis J Hepatol 57 2012 663 674
7. A. Tarhuni, P. Rufat, A. Sutton, and et al. Impact of cytokine gene variants on the prediction and prognosis of hepatocellular carcinoma in patients with cirrhosis J Hepatol 61 2014 342 350
8. Y. Wang, N. Kato, Y. Hoshida, and et al. Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection Hepatology 37 2003 65 71
9. K. Migita, S. Miyazoe, Y. Maeda, and et al. Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection-association between TGF-beta1 polymorphisms and hepatocellular carcinoma J Hepatol 42 2005 505 510
10. P. Nahon, A. Sutton, P. Rufat, and et al. Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis Hepatology 50 2009 1484 1493
11. P. Nahon, A. Sutton, P. Rufat, and et al. A variant in myeloperoxidase promoter hastens the emergence of hepatocellular carcinoma in patients with HCV-related cirrhosis J Hepatol 56 2012 426 432
12. P. Nahon, A. Sutton, P. Rufat, and et al. Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis Gastroenterology 134 2008 102 110
13. E. Lauret, M. Rodríguez, S. González, and et al. HFE gene mutations in alcoholic and virus-related cirrhotic patients with hepatocellular carcinoma Am J Gastroenterol 97 2002 1016 1021
14. X.D. Long, Y. Ma, D.Y. Qu, and et al. The polymorphism of XRCC3 codon 241 and AFB1-related hepatocellular carcinoma in Guangxi population, China Ann Epidemiol 18 2008 572 578
15. J.-M. Yuan, S.C. Lu, D. Van Den Berg, and et al. Genetic polymorphisms in the methylenetetrahydrofolate reductase and thymidylate synthase genes and risk of hepatocellular carcinoma Hepatology 46 2007 749 758
16. N. Dharel, N. Kato, R. Muroyama, and et al. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C Clin Cancer Res 12 2006 4867 4871
17. Y.J. Yoon, H.Y. Chang, S.H. Ahn, and et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection Carcinogenesis 29 2008 1192 1196
18. B.K.A. Dayyeh, M. Yang, B.C. Fuchs, and et al. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma Gastroenterology 141 2011 141 149
19. R. Pinyol, J. Nault, I. Quetglas, and et al. Molecular profiling of liver tumors: classification and clinical translation for decision making Semin Liver Dis 34 2014 363 375
20. E. Schiffer, C. Housset, W. Cacheux, and et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis Hepatology 41 2005 307 314
21. Y. Hoshida, A. Villanueva, A. Sangiovanni, and et al. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis Gastroenterology 144 2013 1024 1030
22. J. Bruix, T. Takayama, V. Mazzaferro, and et al. STORM: a phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma J Clin Oncol 32 2014 5s 2014 (Suppl; Abstr 4006)
23. B. Bressac, M. Kew, J. Wands, and et al. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa Nature 350 1991 429 431
24. B. Wang, G. Huang, D. Wang, and et al. Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis J Hepatol 53 2010 508 518
25. J. Kozlitina, C. Xing, A. Pertsemlidis, and et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease Nat Genet 40 2008 1461 1465
26. Y.L. Liu, G.L. Patman, J.B.S. Leathart, and et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma J Hepatol 61 2014 75 81
27. P. Nahon, L. Valenti, J. Henrion, and et al. Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data Hepatology 59 2014 2170 2177
28. A.G. Singal, H. Manjunath, A.C. Yopp, and et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis Am J Gastroenterol 109 2014 325 334
29. E. Guyot, A. Sutton, P. Rufat, and et al. PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis J Hepatol 58 2013 312 318
30. V. Kumar, N. Kato, Y. Urabe, and et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma Nat Genet 43 2011 455 458
31. D. Miki, H. Ochi, C.N. Hayes, and et al. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers Nat Genet 43 2011 797 800
32. D.-K. Jiang, J. Sun, G. Cao, and et al. Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma Nat Genet 45 2013 72 75
33. R.J. Clifford, J. Zhang, D.M. Meerzaman, and et al. Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma Hepatology 52 2010 2034 2043
34. K.Y.K. Chan, C.-M. Wong, J.S.-H. Kwan, and et al. Genome-wide association study of hepatocellular carcinoma in Southern Chinese patients with chronic hepatitis B virus infection PLoS ONE 6 2011 e28798
35. H. Zhang, Y. Zhai, Z. Hu, and et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers Nat Genet 42 2010 767 770
36. P.A. Farazi, and R.A. Depinho Hepatocellular carcinoma pathogenesis: from genes to environment Nat Rev Cancer 6 2006 674 687
37. International Consensus Group for Hepatocellular Neoplasia Pathologic diagnosis of early hepatocellular carcinoma: a report of the international Consensus Group for Hepatocellular Neoplasia Hepatology 49 2009 658 664
38. A. Satyanarayana, M.P. Manns, and K.L. Rudolph Telomeres and telomerase: a dual role in hepatocarcinogenesis Hepatology 40 2004 276 283
39. R.T. Calado, and N.S. Young Telomere diseases N Engl J Med 361 2009 2353 2365
40. C. Günes, and K.L. Rudolph The role of telomeres in stem cells and cancer Cell 152 2013 390 393
41. D. Hartmann, U. Srivastava, M. Thaler, and et al. Telomerase gene mutations are associated with cirrhosis formation Hepatology 53 2011 1608 1617
42. K.L. Rudolph, S. Chang, M. Millard, and et al. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery Science 287 2000 1253 1258
43. P.A. Farazi, J. Glickman, S. Jiang, and et al. Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma Cancer Res 63 2003 5021 5027
44. J.C. Nault, M. Mallet, C. Pilati, and et al. High frequency of telomerase reverse-transcriptasepromoter somatic mutations in hepatocellularcarcinoma and preneoplastic lesions Nat Commun 4 2013 1 6
45. Y. Totoki, K. Tatsuno, K.R. Covington, and et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes Nat Genet 46 2014 1267 1273
46. W.-K. Sung, H. Zheng, S. Li, and et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma Nat Genet 44 2012 765 769
47. P. Paterlini-Bréchot, K. Saigo, Y. Murakami, and et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene Oncogene 22 2003 3911 3916
48. J.C. Nault, J. Calderaro, L. Di Tommaso, and et al. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis Hepatology 60 2014 1983 1992
49. K. Schulze, S. Imbeaud, E. Letouze, and et al. Exome sequencing of hepatocellular carcinoma identifies new mutations signatures and potential therapeutic targets Nat Genet 47 2015 505 511
50. L. Di Tommaso, A. Sangiovanni, M. Borzio, and et al. Advanced precancerous lesions in the liver Best Pract Res Clin Gastroenterol 27 2013 269 284
51. J.C. Nault, P. Bioulac-Sage, and J. Zucman-Rossi Hepatocellular benign tumors-from molecular classification to personalized clinical care Gastroenterology 144 2013 888 902
52. O. Bluteau, E. Jeannot, P. Bioulac-Sage, and et al. Bi-allelic inactivation of TCF1 in hepatic adenomas Nat Genet 32 2002 312 315
53. S. Rebouissou, M. Amessou, G. Couchy, and et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours Nature 457 2009 200 204
54. J. Zucman-Rossi, E. Jeannot, J.T.V. Nhieu, and et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC Hepatology 43 2006 515 524
55. C. Pilati, J.C. Nault, S. Imbeaud, and et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation Cancer Cell 25 2014 428 441
56. C. Neuveut, Y. Wei, and M.A. Buendia Mechanisms of HBV-related hepatocarcinogenesis J Hepatol 52 2010 594 604
57. C. Brechot, C. Pourcel, A. Louise, and et al. Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma Nature 286 1980 533 535
58. J.C. Nault, S. Datta, S. Imbeaud, and et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas Nat Genet 2015 Aug 24 http://dx.doi.org/10.1038/ng.3389 [Epub ahead of print]
59. T. Helleday, S. Eshtad, and S. Nik-Zainal Mechanisms underlying mutational signatures in human cancers Nat Rev Genet 15 2014 585 598
60. S.L. Poon, S.-T. Pang, J.R. McPherson, and et al. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool Sci Transl Med 5 2013 197 201
61. L.B. Alexandrov, S. Nik-Zainal, D.C. Wedge, and et al. Signatures of mutational processes in human cancer Nature 500 2013 415 421
62. C. Guichard, G. Amaddeo, S. Imbeaud, and et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma Nat Genet 44 2012 694 698
63. J. Huang, Q. Deng, Q. Wang, and et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma Nat Genet 44 2012 1117 1121
64. S.P. Cleary, W.R. Jeck, X. Zhao, and et al. Identification of driver genes in hepatocellular carcinoma by exome sequencing Hepatology 58 2013 1693 1702
65. S.-M. Ahn, S.J. Jang, J.H. Shim, and et al. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification Hepatology 60 2014 1972 1982
66. Z. Kan, H. Zheng, X. Liu, and et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma Genome Res 23 2013 1422 1433
67. M.R. Stratton, P.J. Campbell, and P.A. Futreal The cancer genome Nature 458 2009 719 724
68. A. La Coste de, B. Romagnolo, P. Billuart, and et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas Proc Natl Acad Sci U S A 95 1998 8847 8851
69. S. Satoh, Y. Daigo, Y. Furukawa, and et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1 Nat Genet 24 2000 245 250
70. S. Boyault, D.S. Rickman, A. De Reyniès, and et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets Hepatology 45 2006 42 52
71. A. Lachenmayer, C. Alsinet, R. Savic, and et al. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib Clin Cancer Res 18 2012 4997 5007
72. V. Audard, G. Grimber, C. Elie, and et al. Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations J Pathol 212 2007 345 352 Available at: http://doi.wiley.com/10.1002/path.2169
73. A. Fujimoto, M. Furuta, Y. Shiraishi, and et al. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity Nat Commun 6 2015 1 8
74. I.C. Hsu, R.A. Metcalf, T. Sun, and et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas Nature 350 1991 427 428
75. A. Fujimoto, Y. Totoki, T. Abe, and et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators Nat Genet 44 2012 760 764
76. E.T. Sawey, M. Chanrion, C. Cai, and et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening Cancer Cell 19 2011 347 358
77. K. Wang, H.Y. Lim, S. Shi, and et al. Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma Hepatology 58 2013 706 717
78. M. Li, H. Zhao, X. Zhang, and et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma Nat Genet 43 2011 828 829
79. M.B. Sporn, and K.T. Liby NRF2 and cancer: the good, the bad and the importance of context Nature 12 2012 564 571
80. G.M. DeNicola, F.A. Karreth, T.J. Humpton, and et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis Nature 475 2011 106 109
81. D.Y. Chiang, A. Villanueva, Y. Hoshida, and et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma Cancer Res 68 2008 6779 6788
82. A. Villanueva, D.Y. Chiang, P. Newell, and et al. Pivotal role of mTOR signaling in hepatocellular carcinoma Gastroenterology 135 2008 1972 1983
83. V. Tovar, C. Alsinet, A. Villanueva, and et al. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage J Hepatol 52 2010 550 559
84. E. Douville, and J. Downward EGF induced SOS phosphorylation in PC12 cells involves P90 RSK-2 Oncogene 15 1997 373 383
85. R. Rudalska, D. Dauch, T. Longerich, and et al. RNAi screening identifies a mechanism of sorafenib resistance in liver cancer Nat Med 2014 1 11
86. T.R. Golub Molecular classification of cancer: class discovery and class prediction by gene expression monitoring Science 286 1999 531 537
87. J. DeRisi, L. Penland, P.O. Brown, and et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer Nat Genet 14 1996 457 460
88. M.J. van de Vijver, Y.D. He, L.J. Van't Veer, and et al. A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 2002 1999 2009
89. L.J. Solin, R. Gray, F.L. Baehner, and et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast J Natl Cancer Inst 105 2013 701 710
90. Y. Hoshida, S. Toffanin, A. Lachenmayer, and et al. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements Semin Liver Dis 30 2010 35 51
91. J.-S. Lee, J. Heo, L. Libbrecht, and et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells Nat Med 12 2006 410 416
92. T. Yamashita, M. Forgues, W. Wang, and et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma Cancer Res 68 2008 1451 1461
93. A. Villanueva, Y. Hoshida, C. Battiston, and et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma Gastroenterology 140 2011 1501 1512
94. Y. Hoshida, S.M.B. Nijman, M. Kobayashi, and et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma Cancer Res 69 2009 7385 7392
95. P. Kaposi-Novak Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype J Clin Invest 116 2006 1582 1595
96. C. Coulouarn, V.M. Factor, and S.S. Thorgeirsson Transforming growth factor-β gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer Hepatology 47 2008 2059 2067
97. P. Newell, S. Toffanin, A. Villanueva, and et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo J Hepatol 51 2009 725 733
98. T. Yamashita, and X.W. Wang Cancer stem cells in the development of liver cancer J Clin Invest 123 2013 1911 1918
99. Á. Holczbauer, V.M. Factor, J.B. Andersen, and et al. Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types Gastroenterology 145 2013 221 231
100. S. Cairo, C. Armengol, A. De Reyniès, and et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer Cancer Cell 14 2008 471 484
101. H.G. Woo, J.H. Lee, J.H. Yoon, and et al. Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma Cancer Res 70 2010 3034 3041
102. D. Sia, Y. Hoshida, A. Villanueva, and et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes Gastroenterology 144 2013 829 840
103. A. Villanueva, C. Alsinet, K. Yanger, and et al. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice Gastroenterology 143 2012 1660 1669
104. A. Villanueva, A. Portela, S. Sayols, and et al. DNA Methylation-based prognosis and epidrivers in hepatocellular carcinoma Hepatology 61 2015 1945 1956
105. S. Toffanin, Y. Hoshida, A. Lachenmayer, and et al. MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a Gastroenterology 140 2011 1618 1628
106. J.-S. Lee, I.-S. Chu, J. Heo, and et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling Hepatology 40 2004 667 676
107. V.W. Keng, D. Sia, A.L. Sarver, and et al. Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR Hepatology 57 2012 120 130
108. G. Ciriello, M.L. Miller, B.A. Aksoy, and et al. Emerging landscape of oncogenic signatures across human cancers Nat Genet 45 2013 1127 1133
109. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma J Hepatol 56 2012 908 943
110. J. Bruix, M. Sherman American Association for the Study of Liver Diseases Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
111. Y. Hoshida, A. Moeini, C. Alsinet, and et al. Gene signatures in the management of hepatocellular carcinoma Semin Oncol 39 2012 473 485
112. J. Friemel, M.P. Rechsteiner, L. Frick, and et al. Intratumor heterogeneity in hepatocellular carcinoma Clin Cancer Res 21 2014 1951 1961
113. R.M. Simon, S. Paik, and D.F. Hayes Use of archived specimens in evaluation of prognostic and predictive biomarkers J Natl Cancer Inst 101 2009 1446 1452
114. J.C. Nault, A. De Reyniès, A. Villanueva, and et al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection Gastroenterology 145 2013 176 187
115. T. Yamashita, J. Ji, A. Budhu, and et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features Gastroenterology 136 2009 1012 1124
116. A. Budhu, H.L. Jia, M. Forgues, and et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma Hepatology 47 2008 897 907
117. J. Ji, J. Shi, A. Budhu, and et al. MicroRNA expression, survival, and response to interferon in liver cancer N Engl J Med 361 2009 1437 1447
118. Y. Hoshida, A. Villanueva, M. Kobayashi, and et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma N Engl J Med 359 2008 1995 2004
119. A. Budhu, M. Forgues, Q. Ye, and et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment Cancer Cell 10 2006 99 111
120. J.H. Kim, B.H. Sohn, H.-S. Lee, and et al. Genomic predictors for recurrence patterns of hepatocellular carcinoma: model derivation and validation PLoS Med 11 2014 e1001770
121. P. Jiang, C.W.M. Chan, K.C.A. Chan, and et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients Proc Natl Acad Sci U S A 2015 201500076
122. B. Vogelstein, and S. Zhou Cancer genome landscapes Science 339 2013 1546 1558
123. I.B. Weinstein Cancer. Addiction to oncogenes - the Achilles heal of cancer Science 297 2002 63 64
124. P.B. Chapman, A. Hauschild, C. Robert, and et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
125. A.T. Shaw, D.-W. Kim, K. Nakagawa, and et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med 368 2013 2385 2394
126. J.M. Llovet, S. Ricci, V. Mazzaferro, and et al. Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
127. J.M. Llovet, A. Villanueva, A. Lachenmayer, and et al. Molecular targeted therapies in hepatocellular carcinoma Nat Rev Clin Oncol 12 2015 408 424
128. S.M. Swain, J. Baselga, S.-B. Kim, and et al. Pertuzumab, trastuzumab, and docetaxel in HER2-Positive metastatic breast cancer N Engl J Med 372 2015 724 734
129. E. Horwitz, I. Stein, M. Andreozzi, and et al. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment Cancer Discov 4 2014 730 743
130. J.M. Llovet, C.E.A. Pena, C.D. Lathia, and et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma Clin Cancer Res 18 2012 2290 2300
131. A.B. Siegel, E.I. Cohen, A. Ocean, and et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma J Clin Oncol 26 2008 2992 2998
132. L.R. Desnoyers, R. Pai, R.E. Ferrando, and et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models Oncogene 27 2008 85 97
133. K. Nicholes, S. Guillet, E. Tomlinson, and et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice Am J Pathol 160 2002 2295 2307
134. J.M. Llovet, T. Decaens, J.L. Raoul, and et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study J Clin Oncol 31 2013 3509 3516
135. P.J. Johnson, S. Qin, J.W. Park, and et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study J Clin Oncol 31 2013 3517 3524
136. R.S. Finn, J.P. Crown, I. Lang, and et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol 16 2015 25 35
137. N. Shang, M. Arteaga, A. Zaidi, and et al. FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis Hepatology 61 2015 214 226
138. P. Kaposi-Novak, L. Libbrecht, H.G. Woo, and et al. Central role of c-Myc during malignant conversion in human hepatocarcinogenesis Cancer Res 69 2009 2775 2782
139. J.N. Anastas, and R.T. Moon WNT signalling pathways as therapeutic targets in cancer Nat Rev Cancer 13 2013 1 16
140. K. Inoki, M.N. Corradetti, and K.-L. Guan Dysregulation of the TSC-mTOR pathway in human disease Nat Genet 37 2005 19 24
141. R.S. Finn, R.T.P. Poon, T. Yau, and et al. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma J Hepatol 59 2013 1271 1277
142. A.X. Zhu, M. Kudo, E. Assenat, and et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib JAMA 312 2014 57
143. H.Y. Lim, J. Heo, H.J. Choi, and et al. A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma Clin Cancer Res 20 2014 5976 5985
144. L. Goyal, M.D. Muzumdar, and A.X. Zhu Targeting the HGF/c-MET pathway in hepatocellular carcinoma Clin Cancer Res 19 2013 2310 2318
145. A. Santoro, L. Rimassa, I. Borbath, and et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study Lancet Oncol 14 2013 55 63
146. P. Michieli, and F. Di Nicolantonio Targeted therapies: Tivantinib - a cytotoxic drug in MET inhibitor's clothes? Nat Rev Clin Oncol 10 2013 372 374
147. K. Breuhahn, S. Vreden, R. Haddad, and et al. Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression Cancer Res 64 2004 6058 6064
148. G.K. Abou-Alfa, M. Capanu, E.M. O'Reilly, and et al. A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma J Hepatol 60 2014 319 324
149. C. Robert, G.V. Long, B. Brady, and et al. Nivolumab in previously untreated melanoma without BRAFMutation N Engl J Med 372 2015 320 330
150. F. Shi, M. Shi, Z. Zeng, and et al. PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients Int J Cancer 128 2010 887 896
151. Y. Chen, R.R. Ramjiawan, T. Reiberger, and et al. CXCR4 inhibition in tumor microenvironment facilitates anti-PD-1 immunotherapy in sorafenib-treated HCC in mice Hepatology 61 2015 1591 1602
152. Villa E, Critelli R, Lei B, et al. Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. Gut 2015 (in press, doi: 10.1136/gutjnl-2014-308483).
153. Kim JH, Sohn BH, Lee HS, et al. Genomic predictors for recurrence patterns of hepatocellular carcinoma: model derivation and validation. PLoS Med 2015 (in press, doi: 10.1371/journal.pmed.1001770).
154. S. Roessler, A. Budhu, M. Forgues, and et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients Cancer Res 70 2010 10202 10212
155. J.U. Marquardt, C. Raggi, and J.B. Andersen Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways Hepatology 54 2011 1031 1042
156. C. Coulouarn, V.M. Factor, J.B. Andersen, and et al. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties Oncogene 28 2009 3526 3536
157. R. Wei, G.L. Huang, M.Y. Zhang, and et al. Clinical Significance and prognostic value of microRNA expression signatures in hepatocellular carcinoma Clin Cancer Res 19 2013 4780 4791
158. C. Augello, V. Vaira, L. Caruso, and et al. MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma Liver Int 32 2012 772 782
159. S.R. Viswanathan, J.T. Powers, W. Einhorn, and et al. Lin28 promotes transformation and is associated with advanced human malignancies Nat Genet 41 2009 843 847
160. W. Li, L. Xie, X. He, and et al. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma Int J Cancer 123 2008 1616 1622
161. J. Jiang, Y. Gusev, I. Aderca, and et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival Clin Cancer Res 14 2008 419 427
162. L. Gramantieri, F. Fornari, M. Ferracin, and et al. MicroRNA-221 Targets Bmf in Hepatocellular Carcinoma and Correlates with Tumor Multifocality Clin Cancer Res 15 2009 5073 5081
163. H. Hernandez-Vargas, M.P. Lambert, F. Le Calvez-Kelm, and et al. Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors PLoS ONE 5 2010 e9749
164. D. Calvisi, S. Ladu, A. Gorden, and et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC Gastroenterology 130 2006 1117 1128
165. S. Lee, H.J. Lee, J.-H. Kim, and et al. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis Am J Pathol 163 2003 1371 1378
166. G.Y. Kwon, B.C. Yoo, Koh, and et al. Promoter methylation of E-cadherin in hepatocellular carcinomas and dysplastic nodules J Korean Med Sci 20 2005 242 247